This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Central nervous system, other parts/unspecified
CD2_BENIGN_CNS_NOS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D33
- Name in latin
- Neoplasma benignum alterius partis specificatae systematis nervosi centralis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Central nervous system, other parts/unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Central nervous system, other parts/unspecified
- Benign neoplasm of brain and other parts of central nervous system
- Benign neoplasm of brain and other parts of central nervous system
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 127 | 63 | 64 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 50.87 | 50.19 | 51.55 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 117
- Matched controls
- 1169
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D33.7
ICD-10 Finland
Benign neoplasm: Other specified parts of central nervous system
+∞
110.6
88
*
2259X
ICD-9 Finland
Benign neoplasm of brain and other parts of nervous system, Nervous system, part unspecified
+∞
18.2
17
*
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
44.7
15.9
19
5
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
9.6
13.4
28
37
ABB00
NOMESCO Finland
Excision of lesion of spinal canal
66.1
10.8
12
*
22599
ICD-8 Finland
Benign neoplasm of brain and other parts of nervous system, Unspecified site
+∞
10.6
10
*
H02AB02
ATC
dexamethasone; systemic
40.0
9.2
11
*
9560/0-C72.9
ICD-O-3
Schwannoma, NOS, of nervous system, NOS
+∞
8.4
8
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
24.0
8.2
11
5
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.1
7.8
13
11
D33.30
ICD-10 Finland
Acoustic neuroma
+∞
7.4
7
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
42.5
6.8
8
*
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
73.6
6.5
7
*
D32.02
ICD-10 Finland
Benign tumor of the meninges at the base of the brain
73.6
6.5
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
6.3
6
*
D33.00
ICD-10 Finland
Medial pilosytic astrocytoma of the cerebrum
+∞
6.3
6
*
D33.9
ICD-10 Finland
Benign neoplasm: Central nervous system, unspecified
+∞
6.3
6
*
D32.1
ICD-10 Finland
Benign neoplasm: Spinal meninges
+∞
6.3
6
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
6.3
6
*
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
6.7
6.2
15
25
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
36
167
2.61
5.17
2.4
2.0
2.4
2.4
mmol/l
0.02
29
141
52
299
2.25
4.58
2.4
2.1
2.4
2.3
mmol/l
0.37
43
242
28
131
2.46
3.88
4.6
6.1
—
—
—
0
0
61
393
2.06
3.88
4.9
4.1
—
—
—
0
0
17
63
2.96
3.66
7.9
11.7
1.2
1.6
%
1.00
17
63
17
63
2.96
3.66
8.2
11.7
0.6
0.7
%
0.42
17
63
36
193
2.21
3.65
2.4
2.1
—
—
—
0
0
24
111
2.43
3.39
6.8
12.8
1.2
1.2
mmol/l
0.03
19
92
65
457
1.87
2.98
8.2
7.1
1.2
1.2
mmol/l
0.09
56
400
74
547
1.85
2.85
7.2
6.2
4.4
4.3
e9/l
0.22
66
468
8
20
4.19
2.61
1.5
1.4
—
—
—
0
0
41
259
1.86
2.57
5.0
3.8
0.0
0.0
estimate
0.49
11
77
8
24
3.49
2.22
1.3
1.1
—
—
—
0
0
46
322
1.67
1.96
3.5
3.0
—
—
—
0
0
33
212
1.75
1.91
1.6
1.7
0.9
1.2
mg/l
0.69
26
168
7
22
3.30
1.91
1.1
2.3
—
—
—
0
0
14
67
2.22
1.84
1.9
1.9
0.2
0.2
g/l
0.16
14
57
14
67
2.22
1.84
1.1
1.1
22.2
102.2
iu/ml
—
5
27
91
767
1.66
1.77
5.2
3.8
15.0
14.7
pmol/l
0.48
85
691
62
481
1.56
1.69
4.5
3.5
0.0
0.0
estimate
—
10
81
62
483
1.55
1.65
5.3
4.7
0.0
0.0
estimate
0.00
11
80
89
755
1.60
1.60
4.3
3.9
10.7
11.5
mm/h
0.23
83
687
6
20
3.10
1.60
1.7
1.2
—
—
—
0
0
112
1015
1.88
1.48
17.8
11.9
22.1
23.0
mg/l
0.11
93
764
52
399
1.51
1.44
3.9
3.4
62.2
41.9
ng/l
0.27
39
276
5
17
3.02
1.37
1.0
1.1
—
—
—
0
0
61
488
1.48
1.36
4.6
3.5
0.0
0.0
estimate
0.00
11
76
8
34
2.44
1.32
1.3
1.4
—
—
—
0
0
10
48
2.18
1.31
4.6
2.7
24.8
24.4
mmol/l
—
10
48
24
157
1.65
1.29
1.4
1.7
—
—
—
0
0
114
1050
1.84
1.26
21.4
14.7
3.9
4.0
mmol/l
1.21
114
1019
8
38
2.18
1.21
2.6
1.2
—
—
—
0
0
0
35
0.00
1.17
0.0
2.3
—
94.3
—
0
23
5
20
2.56
1.16
1.0
2.4
4.3
4.1
g/l
—
5
20
30
214
1.53
1.14
2.5
1.9
2.9
2.9
mg/l
0.01
25
183
113
1046
1.73
1.11
21.8
14.6
139.6
139.7
mmol/l
0.15
113
1017
7
33
2.18
1.07
1.1
1.2
—
—
—
0
0
7
34
2.12
1.04
1.1
1.1
—
—
—
0
0
13
77
1.77
0.99
4.2
3.1
—
—
—
0
0
7
37
1.94
0.95
2.6
1.2
2.8
3.1
g/l
—
7
28
17
113
1.58
0.87
1.4
1.7
—
—
—
0
0
47
384
1.36
0.85
5.1
3.5
—
—
—
0
0
8
46
1.79
0.84
2.8
1.5
2.3
8.1
ug/l
—
8
38
17
115
1.55
0.82
1.5
1.7
—
—
—
0
0
25
185
1.44
0.80
1.9
1.6
1404.8
1203.6
nmol/l
0.52
20
139
10
59
1.75
0.78
10.2
8.9
26.8
25.3
mmol/l
—
10
59
9
55
1.68
0.75
1.1
1.3
—
—
—
0
0
7
39
1.84
0.74
2.6
1.9
—
—
—
0
0
23
171
1.42
0.72
1.3
1.2
19.2
34.9
iu/ml
—
5
57
25
319
0.73
0.67
2.5
2.9
29.8
30.7
u/l
0.13
25
302
5
29
1.75
0.64
1.4
1.3
—
—
—
0
0
9
65
1.41
0.52
2.1
1.3
—
—
—
0
0
99
932
1.28
0.51
6.0
4.5
1.8
1.9
mu/l
0.60
93
837
5
32
1.58
0.42
2.0
1.6
—
—
—
0
0
8
59
1.38
0.42
1.1
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
1.6
—
0
8
5
34
1.49
0.41
3.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
5.2
—
0
11
21
172
1.26
0.37
2.1
1.6
—
—
—
0
0
20
239
0.81
0.33
1.2
1.3
0.8
1.6
u/ml
—
10
63
71
662
1.16
0.33
3.4
3.0
—
—
—
0
0
7
54
1.31
0.31
5.4
2.0
1.5
1.3
%
—
7
54
44
402
1.14
0.26
2.4
1.9
88.0
92.6
pmol/l
0.39
26
210
103
996
1.18
0.25
4.0
4.1
1.2
1.3
mmol/l
0.78
94
917
100
965
1.17
0.25
18.4
10.7
81.7
80.4
ml/min/173m2
0.24
89
764
17
143
1.22
0.25
1.9
1.9
29.6
29.7
s
0.04
17
138
44
404
1.14
0.24
2.8
2.4
75.5
76.7
nmol/l
0.16
39
363
5
37
1.37
0.24
1.2
1.6
—
—
—
0
0
113
1104
1.21
0.22
12.2
8.2
24.0
25.7
u/l
0.62
113
1057
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
12
143
0.82
0.20
1.5
1.4
—
—
—
0
0
18
157
1.17
0.18
2.2
2.6
0.4
1.0
e6/l
1.53
13
81
13
151
0.85
0.17
2.8
2.9
6.5
2.9
e6/l
—
8
74
108
1058
1.14
0.15
4.7
5.0
2.8
2.7
mmol/l
0.07
100
985
23
210
1.12
0.13
3.3
3.4
18.1
121.7
ng/l
2.00
16
160
12
105
1.16
0.11
1.7
1.9
—
—
—
0
0
99
970
1.09
0.11
6.0
5.8
38.9
39.7
mmol/mol
0.38
94
905
105
1034
1.09
0.09
4.4
4.5
4.7
4.6
mmol/l
0.09
97
964
104
1026
1.08
0.07
4.3
4.5
1.5
1.5
mmol/l
0.01
96
950
12
111
1.09
0.04
1.5
2.0
—
—
—
0
0
115
1143
1.06
0.01
27.0
17.2
136.3
137.5
g/l
0.39
115
1123
21
206
1.02
0.00
3.0
2.5
0.8
0.8
ug/l
0.08
15
126
29
287
1.01
0.00
4.6
3.7
21.2
24.4
%
0.69
17
126
5
57
0.87
0.00
1.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
67.2
—
0
5
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
9
97
0.92
0.00
1.4
1.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
6
59
1.02
0.00
1.3
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
13.9
—
0
5
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_CNS_NOS_EXALLC – Benign neoplasm: Central nervous system, other parts/unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).